kabutan

Takeda Pharmaceutical Company Limited(4502) Summary

4502
TSE Prime
Takeda Pharmaceutical Company Limited
5,673
JPY
+8
(+0.14%)
Mar 13, 3:30 pm JST
35.58
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
5,698.9
Mar 13, 11:40 pm JST
Summary Chart Historical News Financial Result
PER
58.1
PBR
1.17
Yield
3.53%
Margin Trading Ratio
18.16
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
5,621 JPY 35.30 USD
Previous Close Mar 12
5,665 JPY 35.63 USD
High Mar 13, 10:18 am
5,711 JPY 35.90 USD
Low Mar 13, 9:00 am
5,621 JPY 35.30 USD
Volume
4,109,300
Trading Value
0.02T JPY 0.15B USD
VWAP
5656.22 JPY 35.48 USD
Minimum Trading Value
567,300 JPY 3,558 USD
Market Cap
9.03T JPY 0.06T USD
Number of Trades
5,581
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
5,916
1-Year High Apr 7, 2025
25,323
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 231,100 725,800 3.14
Feb 27, 2026 283,800 716,800 2.53
Feb 20, 2026 295,900 745,000 2.52
Feb 13, 2026 283,700 727,400 2.56
Feb 6, 2026 288,500 766,100 2.66
Company Profile
Takeda Pharmaceutical Company Limited is a leading pharmaceutical company. With the acquisition of Shire, it has become a global industry leader. The company focuses on prescription drugs and is strengthening its development of new cancer medications.
Sector
Pharmaceuticals
Takeda Pharmaceutical Company Limited's main business is the research, development, manufacturing, and sales of pharmaceuticals, with a focus on key business areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company's research and development efforts are concentrated on three areas: innovative biopharmaceuticals in the priority disease areas of gastroenterology and inflammatory diseases, neuroscience, and oncology, along with plasma-derived therapies and vaccines. Takeda is also committed to rare diseases. The company invests in new research and development capabilities and next-generation platforms, leveraging data and digital technologies to enhance innovation quality and accelerate execution. In Japan, Takeda conducts all operations from research and development to sales in-house, while overseas subsidiaries and affiliates handle manufacturing and sales functions in their respective countries.